Global scalp cooling manufacturer to pioneer new research designed to reduce chances of hair loss by 80%
Cancer sufferers who lose their hair as a consequence of chemotherapy will benefit from a major research project that will improve the scalp cooling technology that prevents hair loss.
When a patient comes to us and asks what the chances are of keeping their hair, at the moment we are very fair and say they are 50%. Now we want to take that up to 80% and we believe that greater understanding of the scientific mechanisms will allow us to do that
The research is being now underway and is being pioneered by global scalp cooling manufacturing company, Paxman Coolers of Huddersfield, in conjunction with the biology department of the University of Huddersfield.
The research will be led by key researcher, Omar Hussain, who has a background in the pharmacology of cancer treatment, which he will use towards his PhD.
He joined Paxman’s originally as a researcher on a joint government-sponsored Knowledge Transfer Partnership between the company and the university, designed to establish the scientific basis of scalp cooling and its success rate with different drugs.
He was supervised by the university’s Dr Nik Georgopoulos and Dr Andrew Collett and he co-authored an article in the specialist journal, Toxicology in Vitro , on the findings of the project.
For Paxman’s managing director, Richard Paxman, the research represents an exciting development that will enable further improvements in the treatment and the technology.
“When a patient comes to us and asks what the chances are of keeping their hair, at the moment we are very fair and say they are 50%. Now we want to take that up to 80% and we believe that greater understanding of the scientific mechanisms will allow us to do that,” he said.
Hussain – who has presented his research at several international conferences in tandem with a Paxman team – described how he replicated the effect of scalp cooling in laboratory conditions.
Cells were taken from hair follicles and subjected to a simulation of chemotherapy treatment. Experiments were conducted with different levels of temperature, from 37 degrees Celcius – the normal temperature of the human body – and then lowered. As the temperatures fell, cell survival increased.
“Compared with 37 degrees there are huge differences,” said Hussain. “At low temperatures, cells are being rescued and maintained well and this promotes the cooling effect.”
He added that the optimum temperature for scalp cooling is yet to be finalised, although it is below 22 degrees C.
At low temperatures, cells are being rescued and maintained well and this promotes the cooling effect
After extensive testing and research, Paxman Coolers plans to launch a fourth-generation scalp cooler in 2016. axman said that acceptance of scalp cooling technology was initially slow during the early years of development, but sales have grown by at least 20% annually for the past five years and are expected to accelerate further. Export business is especially strong.